Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 24 citing articles:

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 110
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases
Mitra Pirhaghi, Fatemeh Mamashli, Faezeh Moosavi-Movahedi, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 5, pp. 2097-2117
Closed Access | Times Cited: 15
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases
Elizabeth M. Rhea, Alice Babin, P. C. Thomas, et al.
Tissue Barriers (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 25
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 1061-1075
Open Access | Times Cited: 9
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype
Toshihiro Noguchi, Hiroyuki Katoh, Satoshi Nomura, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 4
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Mashael R. Aljumaah, Jeffrey Roach, Yunan Hu, et al.
Science Advances (2025) Vol. 11, Iss. 14
Closed Access
A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 × FAD mice by modulating mitophagy via the PINK1/Parkin pathway
Rongcong Luo, Yonghai Kang, He Ma, et al.
International Immunopharmacology (2025) Vol. 154, pp. 114612-114612
Closed Access
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335593
Closed Access
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
Giuseppe Lisco, Anna De Tullio, Michele Iovino, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2993-2993
Open Access | Times Cited: 11
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung‐Tai Kuo, et al.
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 4
The neuroprotective effects of cholecystokinin in the brain: antioxidant, anti-inflammatory, cognition, and synaptic plasticity
Hailiang Cui, Zhonghua Li, Hongyu Sun, et al.
Reviews in the Neurosciences (2025)
Closed Access
A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease
Zijuan Zhang, Ming Shi, Zhengmin Li, et al.
Parkinson s Disease (2023) Vol. 2023, pp. 1-13
Open Access | Times Cited: 8
GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for CombatingAlzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review
Mohammad Abubakar, Lokesh Nama, Mohammad Arif Ansari, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 19, pp. 1635-1664
Closed Access | Times Cited: 2
A Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease
Niraj Kumar Singh, Ashini Singh, M. Varshney, et al.
Current Molecular Medicine (2023) Vol. 23, Iss. 9, pp. 889-900
Closed Access | Times Cited: 5
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease
Noor Abdulhameed, Alice Babin, Kim M. Hansen, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Age-related disease: Eyes
Coad Thomas Dow
Aging (2024), pp. 195-204
Closed Access
Banxia Xiexin Decoction Alleviated Cerebral Glucose Metabolism Disorder by Regulating Intestinal Microbiota in APP/PS1 Mice
Chenyan Gao, Gaofeng Qin, Mingcui Zheng, et al.
Chinese Journal of Integrative Medicine (2023) Vol. 30, Iss. 8, pp. 701-712
Closed Access | Times Cited: 1
Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Research Square (Research Square) (2023)
Open Access
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease
Theodora Panagaki, Elisa B. Randi, Csaba Szabó, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 7, pp. 1149-1174
Open Access
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Małgorzata Łupina, Joanna Listos
Current Issues in Pharmacy and Medical Sciences (2023) Vol. 36, Iss. 4, pp. 232-235
Open Access
Page 1

Scroll to top